Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Industry Insights: Key Trends and Growth Estimates
Uncover key drivers, emerging technologies, and competitive movements shaping the chronic inflammatory demyelinating polyneuropathy (cidp) market from 2026–2035 with trusted insights from The Business Research Company
How much larger will the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market be in 2030 compared with 2026?
The chronic inflammatory demyelinating polyneuropathy (cidp) market size has experienced substantial growth in recent years. It is forecast to expand from $2.27 billion in 2025 to $2.46 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.1%. This historical growth can be attributed to enhanced awareness of rare autoimmune neuropathies, wider availability of IVIG therapies, advancements in electrodiagnostic testing, increased specialist neurology care, and improved recognition of CIDP subtypes.
The chronic inflammatory demyelinating polyneuropathy (cidp) market is anticipated to experience substantial expansion in the coming years, projected to reach $3.32 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.8%. This projected growth throughout the forecast period stems from several factors, including the escalating development of targeted immunotherapies, a heightened emphasis on reducing treatment-related side effects, the broadening scope of remote patient monitoring, an increasing need for therapies offering sustained remission, and greater investments in rare disease research. Concurrently, key developments expected during this period involve the rising application of IVIG as a primary treatment, the growing adoption of individualized treatment plans, enhanced integration of advanced diagnostic methods, the spread of home-based treatment approaches, and a stronger focus on managing the disease over the long term.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21144&type=smp
What Drivers Are Guiding Growth Patterns In The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
Future expansion of the chronic inflammatory demyelinating polyneuropathy (CIDP) market is anticipated due to rising healthcare spending. This increase in healthcare expenditure stems from greater investments in medical infrastructure, a heightened need for advanced treatments, broadened insurance coverage, and governmental initiatives aimed at improving healthcare accessibility. Substantial healthcare spending facilitates improved access to sophisticated treatments, prompt diagnosis, and more effective management of CIDP, leading to better patient outcomes and an enhanced quality of life. An example is provided by the Office for National Statistics, a UK-based government department, which reported in May 2024 that total healthcare expenditure experienced a 5.6% rise in nominal terms from 2022 to 2023, representing a notable acceleration compared to the 0.9% growth recorded in 2022. Consequently, the expanding healthcare expenditure is a key factor propelling the growth of the chronic inflammatory demyelinating polyneuropathy (CIDP) market.
How Is The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Divided Into Segments?
The chronic inflammatory demyelinating polyneuropathy (cidp) market covered in this report is segmented –
1) By Treatment: Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis, Physiotherapy, Other Treatments
2) By Route Of Administration: Intravenous, Oral, Other Routes Of Administrations
3) By Diagnosis: Electrodiagnostic Testing, Nerve Conduction, Electromyography (EMG), Spinal Fluid Analysis, Other Diagnosis
4) By Distribution Channel: Hospitals, Pharmacies, Online Pharmacies, Specialty Clinics
5) By End User: Hospitals, Research Institutions, Homecare Settings
Subsegments:
1) By Intravenous Immunoglobulin (IVIG): Standard IVIG Therapy, High-Dose IVIG Therapy
2) By Corticosteroids: Oral Corticosteroids, Intravenous Corticosteroids
3) By Plasmapheresis: Single-Exchange Plasmapheresis, Multiple-Exchange Plasmapheresis
4) By Physiotherapy: Muscle Strengthening Exercises, Balance And Coordination Therapy
5) By Other Treatments: Immunosuppressive Agents, Monoclonal Antibodies
Which Market Trends Are Opening Growth Opportunities In The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
Major companies within the chronic inflammatory demyelinating polyneuropathy (CIDP) market are prioritizing advancements like intravenous immunoglobulin (IVIG) therapy to boost treatment efficacy, improve patient outcomes, and provide more targeted and effective immune modulation for CIDP management. Intravenous immunoglobulin (IVIG) therapy is a medical intervention that involves administering concentrated antibodies from healthy donors to help regulate the immune system and reduce inflammation in autoimmune conditions. For example, in January 2024, Takeda Pharmaceutical Company Limited, a biopharmaceutical enterprise from Japan, reported FDA approval for GAMMAGARD LIQUID as an intravenous immunoglobulin (IVIG) therapy for adults suffering from chronic inflammatory demyelinating polyneuropathy (CIDP). This approval authorizes its use as an induction therapy, beginning with an initial dose followed by regular maintenance doses to facilitate long-term disease management and enhance neuromuscular function.
Which Major Industry Participants Are Leading The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth?
Major companies operating in the chronic inflammatory demyelinating polyneuropathy (cidp) market are Pfizer Inc., Johnson & Johnson, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring (CSL Limited), Grifols S.A., Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Hualan Biological Engineering Inc, argenx SE, Bio Products Laboratory Ltd., Kedrion S.p.A, Biotest AG, Hansa Biopharma AB, UCB SA, Teva Pharmaceutical Industries Ltd, Merck & Co Inc, Roche Holding AG, Biogen Inc, Momenta Pharmaceuticals, Teijin Pharma Limited, Sanquin Plasma Products BV, Fresenius Kabi AG, Immunovant Sciences GmbH, Akari Therapeutics Plc, GeNeuro Pharmaceuticals, MedDay Pharmaceuticals, HanAll Pharma
Access The Complete Report For Deeper Market Insights:
Which Region Is Projected To Lead The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market During The Forecast Period?
North America was the largest region in the chronic inflammatory demyelinating polyneuropathy (CIDP) market in 2025. The regions covered in the chronic inflammatory demyelinating polyneuropathy (cidp) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=21144&type=smp
Browse Through More Reports Similar to the Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market 2026, By The Business Research Company
Optic Nerve Disorders Treatment Market Report 2026
Peripheral Neuropathy Market Report 2026
https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report
Chemotherapy Induced Peripheral Neuropathy Treatment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
